Research progress on the injury mechanisms of post-resuscitation myocardial dysfunction
Chen Li-min, Yang Min
The Laboratory of Cardiopulmonary Resuscitation and Critical Care Medicine, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China
陈立旻，杨旻. 复苏后心功能障碍损伤机制的研究进展[J]. 中国急救医学, 2018, 38(12): 1109-1112.
Chen Li-min, Yang Min. Research progress on the injury mechanisms of post-resuscitation myocardial dysfunction. Chinese Journal of Critical Care Medicine, 2018, 38(12): 1109-1112.
［1］Kleinman ME, Perkins GD, Bhanji F, et al. ILCOR scientific knowledge gaps and clinical research priorities for cardiopulmonary resuscitation and emergency cardiovascular care: a consensus statement［J］. Circulation, 2018, 137(22): e802-e819.
［2］Bagheri F, Khori V, Alizadeh AM, et al. Reactive oxygen species-mediated cardiac-reperfusion injury: mechanisms and therapies［J］. Life Sci, 2016, 165: 43-55.
［3］Cadenas S. ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection［J］. Free Radic Biol Med, 2018, 117: 76-89.
［4］Cabrera-Fuentes HA, Aragones J, Bernhagen J, et al. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”［J］. Basic Res Cardiol, 2016, 111(6): 69.
［5］汪永生，王连生. 治疗性低温处理心肌缺血/再灌注损伤的研究进展［J］. 中国急救医学, 2017, 37(9): 855-859.
［6］Heusch G, Kleinbongard P. Ivabradine: cardioprotection by and beyond heart rate reduction［J］. Drugs, 2016, 76(7): 733-740.
［7］Zaha VG, Qi D, Su KN, et al. AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia ［J］. J Mol Cell Cardiol, 2016, 91: 104-113.
［8］Daskalopoulos EP, Dufeys C, Bertrand L, et al. AMPK in cardiac fibrosis and repair: Actions beyond metabolic regulation ［J］. J Mol Cell Cardiol, 2016, 91: 188-200.
［9］Chang W, Zhang M, Li J, et al. Berberine attenuates ischemia-reperfusion injury via regulation of adenosine-5′-monophosphate kinase activity in both non-ischemic and ischemic areas of the rat heart［J］. Cardiovasc Drugs Ther, 2012, 26(6): 467-478.
［10］Timmermans AD, Balteau M, Gélinas R， et al. A-769662 potentiates the effect of other AMP-activated protein kinase activators on cardiac glucose uptake ［J］. Am J Physiol Heart Circ Physiol, 2014, 306 (12): H1619-1630.
［11］Morrison A, Chen L, Wang J, et al. Sestrin2 promotes LKB1-mediated AMPK activation in the ischemic heart［J］. FASEB J, 2015, 29 (2): 408-417.
［12］Ma Y, Wang J, Gao J, et al. Antithrombin up-regulates AMP-activated protein kinase signaling during myocardial ischaemia/reperfusion injury［J］. Thromb Haemost, 2015, 113 (2): 338-349.
［13］Kambara T, Shibata R, Ohashi K, et al. C1q/tumor necrosis factor-related protein 9 protects against acute myocardial injury through an adiponectin receptor IAMPK-dependent mechanism［J］. Mol Cell Biol, 2015, 35 (12): 2173-2185.
［14］Vaca Jacome AS， Rabilloud T, Schaeffer-Reiss C, et al. N-terminome analysis of the human mitochondrial proteome［J］. Proteomics, 2015, 15 (14): 2519-2524.
［15］Mnatsakanyan N, Beutner G, Porter GA, et al. Physiological roles of the mitochondrial permeability transition pore［J］. J Bioenerg Biomember, 2017, 49 (1): 13-25.
［16］Biasutto L, Azzolini M, Szabò I et al. The mitochondrial permeability transition pore in AD 2016: An update［J］. Biochim Biophys Acta, 2016, 1863 (10): 2515-2530.
［17］Ghaderi S, Alidadiani N, Dilaver N, et al. Role of glycogen synthase kinase following myocardial infarction and ischemia-reperfusion［J］. Apoptosis, 2017, 22 (7): 887-897.
［18］Ferrari R, Rizzo P. The Notch pathway: a novel target for myocardial remodelling therapy［J］. Eur Heart, 2014, 35 (32): 2140-2145.
［19］Li Y, Hiroi Y, Ngoy S, et al. Notch1 in bone marrow-derived cells mediates cardiac repair after myocardial infarction［J］. Circulation, 2011, 123(8): 866-876.
［20］周学亮，方义湖，赵勇. Notch1减轻心肌缺血再灌注损伤作用的研究［J］. 中华医学杂志, 2016, 96 (20): 1591-1596.
［21］Nistri S, Sassoli C, Bani D. Notch Signaling in Ischemic Damage and Fibrosis: Evidence and Clues from the Heart［J］. Front Pharmacol, 2017, 8: 187.
［22］Boopathy AV, Martinez MD, Smith AW, et al. Intramyocardial delivery of notch ligand-containing hydrogels improves cardiac function and angiogenesis following infarction［J］. Tissue Eng Part A, 2015, 21(17-18): 2315-2322.
［23］Felician G, Collesi C, Lusic M, et al. Epigenetic modification at Notch responsive promoters blunts efficacy of inducing notch pathway reactivation after myocardial infarction［J］. Circ Res, 2014, 115(7): 636-649.
［24］Zhang M, Pan X, Zou Q, et al. Notch3 Ameliorates Cardiac Fibrosis After Myocardial Infarction by Inhibiting the TGF-β1/Smad3 Pathway［J］.Cardiovasc Toxicol, 2016, 16(4): 316-324.
［25］Meng X, Yang J, Dong M, et al. Regulatory T cells in cardiovascular diseases［J］. Nat Rev Cardiol, 2016, 13(3): 167-179.
［26］Wang YP, Xie Y, Ma H, et al. Regulatory T lymphocytes in myocardial infarction: A promising new therapeutic target［J］. Int J Cardiol, 2016, 203: 923-928.
［27］Ong SB, Hernández-Reséndiz S, Crespo-Avilan GE, et al. Inflammation following acute myocardial infarction: Multiple players, dynamicroles, and novel therapeutic opportunities［J］. Pharmacol Ther, 2018, 186: 73-87.
［28］Cohen I, Rider P, Vornov E, et al. IL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity ［J］. Sci Rep, 2015, 5: 14756.
［29］Mauro AG, Mezzaroma E, Torrado J, et al. Reduction of Myocardial ischemia-reperfusion injury by inhibiting interleukin-1 alpha ［J］. J Cardiovasc Pharmacol, 2017, 69(3): 156-160.
［30］Toldo S, Mezzaroma E, Mauro AG, et al. The inflammasome in myocardial injury and cardiac remodeling ［J］. Antioxid Redox Signal, 2015, 22(13): 1146-1161.
［31］Sugiyama K, Muroi M, Kinoshita M, et al. NF-κB activation via MyD88-dependent Toll-like receptor signaling is inhibited by trichothecene mycotoxin deoxynivalenol ［J］. J Toxicol Sci, 2016, 41(2):273-279.
［32］Liu X, Yu Z, Huang X, et al. Peroxisome proliferator-activated receptor γ (PPARγ) mediates the protective effect of quercetin against myocardial ischemia-reperfusion injury via suppressing the NF-κB pathway ［J］. Am J Transl Res, 2016, 8(12): 5169-5186.
［33］Lu M, Tang F, Zhang J, et al. Astragaloside IV attenuates injury caused by myocardial ischemia/reperfusion in rats via regulation of Toll-like receptor 4/nuclear factor-kappaB signaling pathway ［J］. Phytother Res, 2015, 29(4): 599-606.
［34］Han D, Wei J, Zhang R, et al. Hydroxysafflor yellow A alleviates myocardial ischemia/reperfusion in hyperlipidemic animals through the suppression of TLR4 signaling ［J］. Sci Rep, 2016, 6: 35319.
